Single-agent ibrutinib in RESONATE-2TM and RESONATETM versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F19%3A10401961" target="_blank" >RIV/00064165:_____/19:10401961 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/19:00112598 RIV/00216208:11110/19:10401961 RIV/00216208:11150/19:10401961 RIV/65269705:_____/19:00071837 and 2 more
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=7hyBTh8ZPN" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=7hyBTh8ZPN</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00277-019-03830-8" target="_blank" >10.1007/s00277-019-03830-8</a>
Alternative languages
Result language
angličtina
Original language name
Single-agent ibrutinib in RESONATE-2TM and RESONATETM versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia
Original language description
After analyzing treatment patterns in chronic lymphocytic leukemia (CLL) (objective 1), we investigated the relative effectiveness of ibrutinib versus other commonly used treatments (objective 2) in patients with treatment-naïve and relapsed/refraktory CLL, comparing patient-level data from two randomized registration trials with two real-world databases. Hazard ratios (HR) and 95% confidence intervals (CIs) were estimated using a multivariate Cox proportional hazards model, adjusted for differences in baseline characteristics. Rituximab-containing regimens were often prescribed in clinical practice. The most frequently prescribed regimens were fludarabine + cyclophosphamide + rituximab (FCR, 29.3%), bendamustine + rituximab (BR, 17.7%), and other rituximab-containing regimens (22.0%) in the treatment-naïve setting (n = 604), other non-FCR/BR rituximabcontaining regimens (38.7%) and non-rituximab-containing regimens (28.5%) in the relapsed/refractory setting (n = 945). Adjusted HRs (95% CI) for progression-free survival (PFS) and overall survival (OS), respectively, with ibrutinib versus realworld regimens were 0.23 (0.14-0.37; p < 0.0001) and 0.40 (0.22-0.76; p = 0.0048) in the treatment-naïve setting, and 0.21 (0.16-0.27; p < 0.0001) and 0.29 (0.21-0.41; p < 0.0001) in the relapsed/refractory setting. When comparing real-world use of ibrutinib (n = 53) versus other real-world regimens in relapsed/refractory CLL (objective 3), adjusted HRs (95% CI) were 0.37 (0.22-0.63; p = 0.0003) for PFS and 0.53 (0.27-1.03; p < 0.0624) for OS. This adjusted analysis, based on nonrandomized patient data, suggests ibrutinib to be more effective than other commonly used regimens for CLL.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Annals of Hematology
ISSN
0939-5555
e-ISSN
—
Volume of the periodical
98
Issue of the periodical within the volume
12
Country of publishing house
DE - GERMANY
Number of pages
12
Pages from-to
2749-2760
UT code for WoS article
000497186800001
EID of the result in the Scopus database
2-s2.0-85075390148